How Imjudo Works Against Liver Cancer
Imjudo (tremelimumab) is a monoclonal antibody that targets CTLA-4, a protein on T cells that acts as a brake on the immune system. By blocking CTLA-4, Imjudo releases this brake, allowing T cells to attack and destroy hepatocellular carcinoma (HCC) cells, the most common type of liver cancer.[1]
FDA Approval and Dosing for Liver Cancer
The FDA approved Imjudo in October 2022 for unresectable HCC in adults who received prior systemic therapy, based on the HIMALAYA trial. It's given as a single 80 mg intravenous infusion on day 1, combined with durvalumab (Imfinzi) every 4 weeks. This regimen showed a 22% reduction in death risk versus sorafenib, with median overall survival of 16.4 months versus 13.8 months.[2][3]
How the Imjudo-Durvalumab Combo Improves Outcomes
Durvalumab blocks PD-L1 on cancer cells, targeting a different immune checkpoint. Together, they enhance T-cell activation more effectively than single agents. In HIMALAYA, the combo delayed disease progression (median 3.8 months vs. 4.1 months for sorafenib) and had a 20.7% serious adverse event rate, lower than sorafenib's 36.9%.[1][2] No patent data specific to this indication appears on DrugPatentWatch.com.
Common Side Effects Patients Experience
Fatigue (up to 50%), rash, diarrhea, and pruritus occur frequently. Immune-related issues like hepatitis, pneumonitis, or endocrinopathies affect 10-20% of patients, sometimes requiring steroids or treatment interruption.[3]
Who Qualifies and When It's Used First-Line
Unlike its second-line approval, updated data supports first-line use in some cases alongside durvalumab, especially for patients ineligible for atezolizumab-bevacizumab. It's not for Child-Pugh C liver disease due to limited trial data.[1]
Comparison to Other Liver Cancer Treatments
| Treatment | Mechanism | Median OS (HIMALAYA-like trials) | Key Edge |
|-----------|-----------|----------------------------------|----------|
| Imjudo + Durvalumab | CTLA-4 + PD-L1 blockade | 16.4 months | Oral-free, lower discontinuation (8.4%)[2] |
| Atezolizumab + Bevacizumab (Tecentriq + Avastin) | PD-L1 + VEGF inhibition | 19.2 months (IMbrave150) | Higher response rate (30%), but IV + bleeding risk[4] |
| Sorafenib (Nexavar) | Multi-kinase inhibitor | 13.8 months | Single-agent standard, but higher toxicity[1] |
Ongoing Trials and Future Availability
Phase 3 trials like POSH study Imjudo combos in earlier-stage HCC or post-resection. No U.S. biosimilars yet; AstraZeneca holds exclusivity through at least 2033 for related patents.[5]
Sources
[1]: FDA Label for Imjudo
[2]: HIMALAYA Trial (NEJM)
[3]: AstraZeneca Prescribing Info
[4]: IMbrave150 Trial (NEJM)
[5]: DrugPatentWatch.com - Tremelimumab Patents